Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 48 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
Follow-Up Questions
Who is the CEO of Sequana Medical NV?
Ian Crosbie is the Chief Executive Officer of Sequana Medical NV, joining the firm since 2019.
What is the price performance of SQNMF stock?
The current price of SQNMF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Sequana Medical NV?
Sequana Medical NV belongs to Health Care industry and the sector is Health Care
What is Sequana Medical NV market cap?
Sequana Medical NV's current market cap is $NaN
Is Sequana Medical NV a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Sequana Medical NV, including 4 strong buy, 4 buy, 2 hold, 0 sell, and 4 strong sell
